Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports

[1]  S. Stahl,et al.  Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy , 2014, CNS Spectrums.

[2]  S. Stahl.  Emerging guidelines for the use of antipsychotic polypharmacy. , 2013, Revista de psiquiatria y salud mental.

[3]  S. Stahl.  Emerging guidelines for the use of antipsychotic polypharmacy. , 2013, Revista de psiquiatria y salud mental.

[4]  S. Stahl,et al.  “Meta-guidelines” for the management of patients with schizophrenia , 2013, CNS Spectrums.

[5]  C. Correll,et al.  Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice. , 2012, The Psychiatric clinics of North America.

[6]  C. Correll,et al.  Antipsychotics Associated with the Development of Type 2 Diabetes in Antipsychotic-Naïve Schizophrenia Patients , 2010, Neuropsychopharmacology.

[7]  A. Bate,et al.  Quantitative signal detection using spontaneous ADR reporting , 2009, Pharmacoepidemiology and drug safety.

[8]  C. Correll,et al.  Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. , 2009, Schizophrenia bulletin.

[9]  M. Woodward,et al.  First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. , 2008, The British journal of psychiatry : the journal of mental science.

[10]  M. De Hert,et al.  Abnormal glucose metabolism in patients treated with antipsychotics. , 2007, Diabetes & metabolism.

[11]  Peter B. Jones,et al.  Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). , 2006, Archives of general psychiatry.

[12]  J. Lieberman,et al.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.

[13]  C. Correll,et al.  Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics , 2005, BMC psychiatry.

[14]  J. Levine,et al.  Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. , 2004, Psychiatric services.

[15]  Julie Kreyenbuhl,et al.  Practice guideline for the treatment of patients with schizophrenia , 1997 .

[16]  Julie Kreyenbuhl,et al.  The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. , 2010, Schizophrenia bulletin.

[17]  P. Doraiswamy,et al.  Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Event database: a systematic Bayesian signal detection analysis. , 2009, Psychopharmacology bulletin.

[18]  D. Charney,et al.  Discovering the neural basis of human social anxiety: a diagnostic and therapeutic imperative. , 2004, The American journal of psychiatry.

[19]  M. Lindquist,et al.  A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions , 2002, Pharmacoepidemiology and drug safety.

[20]  J. Newcomer,et al.  Hyperglycemia and antipsychotic medications. , 2001, The Journal of clinical psychiatry.